Novavax, Inc.’s proposed COVID-19 vaccine easily cruised to a favorable recommendation for emergency use authorization from the US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee, but a warning about a risk of myocarditis also seems inevitable.
The committee voted 21-0 with one abstention on 7 June that the benefits of the vaccine outweigh the risks and...